LUDIOMIL Drug Patent Profile

« Back to Dashboard

Which patents cover Ludiomil, and when can generic versions of Ludiomil launch?

Ludiomil is a drug marketed by Novartis and is included in one NDA.

The generic ingredient in LUDIOMIL is maprotiline hydrochloride. There is one drug master file entry for this compound. Additional details are available on the maprotiline hydrochloride profile page.

Summary for LUDIOMIL

US Patents:	0
Applicants:	1
NDAs:	1
Raw Ingredient (Bulk) Api Vendors:	96
Patent Applications:	1,262
DailyMed Link:	LUDIOMIL at DailyMed

US Patents and Regulatory Information for LUDIOMIL

Applicant	Tradename	Generic Name	Dosage	NDA	Approval Date	TE	Type	RLD	RS	Patent No.	Patent Expiration	Product	Substance	Delist Req.	Exclusivity Expiration
Novartis	LUDIOMIL	maprotiline hydrochloride	TABLET;ORAL	017543-001	Approved Prior to Jan 1, 1982		DISCN	No	No
Novartis	LUDIOMIL	maprotiline hydrochloride	TABLET;ORAL	017543-002	Approved Prior to Jan 1, 1982		DISCN	No	No
Novartis	LUDIOMIL	maprotiline hydrochloride	TABLET;ORAL	017543-003	Sep 30, 1982		DISCN	No	No

Ludiomil Market Dynamics and Financial Trajectory: Maprotiline Patent, Regulatory, and Commercial Analysis

Last updated: September 26, 2026

Ludiomil is the former brand name for maprotiline hydrochloride, a tetracyclic antidepressant developed by Ciba-Geigy, now part of Novartis. Its commercial position has declined sharply because core compound protection expired decades ago, branded promotion ended in major markets, and generic maprotiline occupies a small, mature segment. Current value is concentrated in legacy prescriptions, niche psychiatric use, and low-cost generic supply rather than branded pharmaceutical growth.

What is Ludiomil and how is maprotiline used?

Ludiomil contains maprotiline hydrochloride, a tetracyclic antidepressant with pharmacology related to tricyclic antidepressants. It primarily inhibits norepinephrine reuptake and has substantial antihistaminic activity. Historical indications included depressive illness, particularly depression associated with anxiety or agitation.

Maprotiline was marketed in tablet formulations, commonly at 25 mg, 50 mg, and 75 mg strengths. Product availability has varied by country. In many jurisdictions, it is no longer actively promoted, and treatment has shifted toward selective serotonin reuptake inhibitors, serotonin-norepinephrine reuptake inhibitors, atypical antidepressants, and newer therapies.

The drug has safety limitations that affect its market position. Seizure risk, cardiac conduction effects, anticholinergic effects, sedation, and overdose toxicity have constrained use relative to newer antidepressants. These characteristics make maprotiline a niche product even where generic supply remains available.

When did Ludiomil lose exclusivity?

Ludiomil lost meaningful commercial exclusivity during the late 20th century. Maprotiline was introduced internationally in the 1970s and reached the U.S. market in the early 1980s. Any original compound patent protection would have expired no later than the late 1990s, before modern products benefited from the current 20-year patent term framework.

Asset	Assessment
Active ingredient	Maprotiline hydrochloride
Original developer	Ciba-Geigy
Current corporate successor	Novartis
Initial commercial era	1970s
U.S. regulatory era	Early 1980s
Core compound exclusivity	Expired decades ago
Current branded exclusivity	None identified
Generic competition	Established historically
Current commercial model	Mature, low-cost, fragmented supply

The key commercial issue is not the expiration of a single recent patent. It is the complete aging of the product franchise. No meaningful patent-based barrier is expected to prevent generic substitution.

What patents protect Ludiomil and maprotiline?

No commercially relevant active patent estate is associated with Ludiomil today. The original composition-of-matter and early formulation patents would have expired long ago. Any remaining patents related to maprotiline would need to cover a narrowly defined formulation, manufacturing process, or delivery method, but no such protection is known to support a material branded franchise.

What is the Orange Book status of Ludiomil?

Ludiomil is not a current U.S. branded growth product with an active Orange Book patent listing. FDA Orange Book records distinguish between approved applications, discontinued products, and patents listed by current applicants. A legacy product can remain historically associated with an approved application without having active commercial exclusivity.

The FDA classifies a drug product as discontinued for several reasons, including commercial discontinuation. Discontinuation does not automatically mean that the product was withdrawn for safety reasons. For Ludiomil, the commercial explanation is consistent with an old branded product displaced by generic antidepressants and newer therapeutic classes (U.S. Food and Drug Administration [FDA], n.d.-a).

Are there formulation patents for Ludiomil?

No formulation patent is known to create a material current barrier to generic maprotiline. Conventional immediate-release tablets are technically straightforward to manufacture. There is no widely commercialized extended-release, transdermal, depot, or specialty delivery platform associated with Ludiomil.

A company seeking to revive the molecule would need to develop a differentiated product, such as an extended-release formulation or a defined psychiatric subpopulation, and obtain new patent protection around the formulation, method of use, or delivery system. That strategy would face clinical, regulatory, and market-economics hurdles.

What is the FDA regulatory status of maprotiline?

Maprotiline has historical FDA approval as an antidepressant, but Ludiomil is not a current branded U.S. commercial growth product. The original U.S. label includes warnings concerning seizure risk, cardiovascular effects, suicidality monitoring, and overdose toxicity (FDA, n.d.-b).

The regulatory profile has several commercial consequences:

1. A generic applicant can rely on the established active ingredient and historical safety record through an abbreviated pathway, subject to current FDA requirements.
2. A new branded formulation would need to establish bioequivalence, clinical value, or a meaningful delivery advantage.
3. A reformulated product would face a narrow opportunity because physicians have many established alternatives.
4. Pediatric, geriatric, and overdose-related safety considerations would complicate promotional positioning.

Maprotiline is therefore a legacy approved molecule rather than a platform with substantial regulatory exclusivity potential.

How large is the current Ludiomil market?

Public financial disclosures do not identify material current Ludiomil revenue for Novartis or another major pharmaceutical company. The brand’s revenue trajectory is best characterized as follows:

Period	Commercial position	Financial direction
1970s-1980s	Branded antidepressant launch and expansion	Growth
1990s	Mature branded product with increasing generic pressure	Plateau to decline
2000s	Brand erosion and reduced promotion	Sharp decline
2010s	Legacy generic availability in selected markets	Low, fragmented revenue
2020s	Niche or limited-market product	No evidence of material branded growth

Ludiomil does not appear to be a separately reported revenue line in Novartis annual reports. Novartis reports results by business unit and major brands, not by every legacy product. The absence of a reported Ludiomil line is consistent with negligible revenue relative to the company’s operating scale, but it does not establish that every maprotiline product has disappeared globally (Novartis, 2024).

What is the revenue exposure for Novartis?

Direct revenue exposure is likely immaterial. Novartis has shifted capital toward innovative medicines, oncology, immunology, cardiovascular therapies, neuroscience, and radioligand medicines. A mature tetracyclic antidepressant without active exclusivity does not fit the company’s current portfolio strategy.

The principal financial effects are likely limited to:

• residual licensing or distribution income in selected territories;
• product-registration maintenance costs;
• pharmacovigilance and regulatory obligations;
• possible divestiture or local-market transfer economics;
• low-margin generic or legacy-brand sales outside core reporting categories.

No evidence indicates that Ludiomil has a material effect on Novartis revenue, operating profit, or valuation.

Which companies are challenging Ludiomil exclusivity?

Generic competition historically came from multiple manufacturers after patent and regulatory exclusivity ended. In the U.S., generic maprotiline supply has been limited compared with high-volume antidepressants such as fluoxetine, sertraline, escitalopram, venlafaxine, and bupropion.

Current manufacturer participation can change because companies discontinue low-volume products when manufacturing, quality, or distribution costs exceed revenue. The commercial challenge is therefore generic availability rather than a named litigation campaign.

Are there Paragraph IV challenges involving maprotiline?

No material current Paragraph IV litigation is associated with Ludiomil or maprotiline. The reason is commercial and legal: Paragraph IV litigation is relevant when an applicant challenges an unexpired listed patent. Maprotiline’s core exclusivity expired decades ago, and no major active Orange Book patent dispute is publicly associated with the product.

What patent litigation affects Ludiomil?

No significant current patent litigation affecting Ludiomil is identified. The drug’s relevant legal risks are more likely to involve:

• product-liability claims;
• manufacturing or quality compliance;
• trademark ownership and brand use;
• local registration status;
• supply interruptions;
• prescription labeling and pharmacovigilance.

Patent litigation is not a meaningful current value driver for this product.

How strong is the Ludiomil patent estate?

The current patent estate is weak for commercial purposes.

Patent factor	Current assessment
Composition-of-matter protection	Expired
Basic tablet protection	Expired or commercially irrelevant
Active Orange Book exclusivity	None of material significance identified
Method-of-use protection	No current commercially meaningful estate identified
Manufacturing barriers	Low to moderate
Regulatory switching barrier	Low for established generic products
Brand differentiation	Low
Litigation leverage	Minimal

Manufacturing maprotiline hydrochloride is less strategically difficult than manufacturing complex biologics, sterile injectables, long-acting formulations, or high-potency oncology products. The main barriers are demand forecasting, regulatory compliance, batch economics, and distribution, not proprietary chemistry.

What generic entry risks exist for Ludiomil?

Generic entry risk is effectively permanent because the product is already a legacy generic molecule. The relevant risk is not future entry into a protected market. It is continued erosion of supply and brand relevance.

Potential market outcomes include:

• continued low-volume generic availability;
• withdrawal by one or more manufacturers;
• regional shortages caused by low production incentives;
• substitution by newer antidepressants;
• persistence in countries where physicians retain familiarity with maprotiline;
• price compression if multiple suppliers remain active.

Because the product is inexpensive and mature, generic manufacturers have limited incentive to invest in broad promotional campaigns. Prescribing is more likely to persist through physician habit, patient response, and local formulary practice.

How does Ludiomil compare with competing antidepressants?

Product or class	Exclusivity status	Current market strength	Commercial comparison
Ludiomil/maprotiline	Expired	Niche	Low-cost legacy use
Sertraline	Expired	High	Broad generic availability
Fluoxetine	Expired	High	Large historical and generic market
Escitalopram	Expired	High	Strong physician familiarity
Venlafaxine	Expired	High	Broad use, multiple formulations
Bupropion	Expired	High	Differentiated clinical positioning
Mirtazapine	Expired	Moderate to high	Useful sedating and appetite-related profile
Vortioxetine	Active or recent branded protection in some markets	Branded	Higher pricing and differentiated positioning

Maprotiline’s competitive disadvantage is not merely age. It lacks a current commercial narrative that is strong enough to overcome safety concerns and the availability of better-known alternatives.

What licensing deals involve Ludiomil?

No recent major licensing transaction involving Ludiomil has been publicly disclosed by Novartis or a major pharmaceutical company. Historic rights may have been distributed through local affiliates, distributors, or regional licensees, but those arrangements are unlikely to generate material transaction value today.

A potential deal would more likely involve a regional generic manufacturer acquiring registration rights or distribution rights than a global pharmaceutical company licensing a strategic innovation asset.

What is the geographic coverage of Ludiomil?

Maprotiline has had international regulatory exposure, but current availability is uneven. The product may remain registered or marketed in selected countries in Europe, Asia, Latin America, the Middle East, and other markets, while being unavailable or commercially inactive elsewhere.

Geographic coverage depends on:

• local renewal of marketing authorization;
• continued manufacturer interest;
• national formularies;
• local generic-substitution rules;
• pharmacovigilance obligations;
• demand from psychiatrists and hospitals.

A global revenue estimate cannot be inferred from historic multinational availability. Registration in a country does not establish active sales or meaningful market share.

What generic launch scenarios are likely?

Base case

Maprotiline remains a low-volume generic product in selected markets. Prices remain low, manufacturers operate with limited promotional investment, and prescribing gradually declines.

Downside case

Manufacturers exit low-volume markets. Patients and physicians transition to other antidepressants, and local availability becomes intermittent. The active ingredient remains legally available but commercially difficult to source.

Upside case

A manufacturer develops a differentiated formulation or secures a niche indication. This could create temporary pricing power, but it would require new clinical data, regulatory investment, and patent protection. The probability is low given the competitive antidepressant market.

Key Takeaways

• Ludiomil is the legacy brand for maprotiline hydrochloride.
• Core patent and regulatory exclusivity expired decades ago.
• No material active Orange Book patent estate or current Paragraph IV litigation is associated with the product.
• Novartis has no publicly disclosed material Ludiomil revenue exposure.
• Current value is concentrated in limited generic and regional markets.
• Generic supply, not patent protection, determines commercial continuity.
• New product development would require a differentiated formulation, indication, or delivery system.
• The financial trajectory is mature, declining, and commercially immaterial at the global pharmaceutical-company level.

FAQs

Is Ludiomil still available in the United States?

Ludiomil is not a significant current U.S. branded product. Historical maprotiline approval and generic availability should be distinguished from active commercial distribution.

Is maprotiline a generic drug?

Yes. Maprotiline hydrochloride is a generic active ingredient, although availability varies by country and manufacturer.

Does Novartis still sell Ludiomil?

No material current global commercialization by Novartis is publicly evident. Local legacy registrations or distribution arrangements may differ by market.

Can a company obtain new patents on maprotiline?

A company could seek patents on a novel formulation, delivery system, manufacturing process, or method of use. New patent protection would not restore the expired compound patent.

Is maprotiline commercially attractive for a generic manufacturer?

Only on a limited regional basis. The product may be viable where competition is low and demand is stable, but its small market, safety profile, and declining prescribing limit scale.

References

1. Novartis AG. (2024). Annual report 2023. https://www.novartis.com/investors/annual-report

2. U.S. Food and Drug Administration. (n.d.-a). Approved drug products with therapeutic equivalence evaluations. https://www.fda.gov/drugs/drug-approvals-and-databases/orange-book-data-files

3. U.S. Food and Drug Administration. (n.d.-b). Maprotiline hydrochloride prescribing information. FDA drug labeling database. https://www.accessdata.fda.gov/scripts/cder/daf/

4. National Library of Medicine. (n.d.). Maprotiline hydrochloride drug information. DailyMed. https://dailymed.nlm.nih.gov/dailymed/